Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$16.3 million.

  • 10x Genomics' Income from Continuing Operations rose 6685.16% to -$16.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$43.5 million, marking a year-over-year increase of 7615.69%. This contributed to the annual value of -$43.5 million for FY2025, which is 7615.69% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Income from Continuing Operations is -$16.3 million, which was up 6685.16% from -$27.5 million recorded in Q3 2025.
  • 10x Genomics' Income from Continuing Operations' 5-year high stood at $34.5 million during Q2 2025, with a 5-year trough of -$93.0 million in Q3 2023.
  • Over the past 5 years, 10x Genomics' median Income from Continuing Operations value was -$36.8 million (recorded in 2024), while the average stood at -$35.3 million.
  • Per our database at Business Quant, 10x Genomics' Income from Continuing Operations plummeted by 48322.48% in 2022 and then surged by 19113.65% in 2025.
  • 10x Genomics' Income from Continuing Operations (Quarter) stood at -$18.4 million in 2021, then increased by 6.69% to -$17.2 million in 2022, then plummeted by 184.36% to -$49.0 million in 2023, then dropped by 0.16% to -$49.0 million in 2024, then soared by 66.85% to -$16.3 million in 2025.
  • Its Income from Continuing Operations stands at -$16.3 million for Q4 2025, versus -$27.5 million for Q3 2025 and $34.5 million for Q2 2025.